Research analysts at Stifel Nicolaus initiated coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a research report issued to clients and investors on Monday, TipRanks reports. The brokerage set a “buy” rating and a $21.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price suggests a potential upside of 42.76% from the company’s previous close.
Several other research firms also recently weighed in on HRTX. FIX assumed coverage on Heron Therapeutics in a research report on Monday, May 18th. They set an “add” rating on the stock. Northland Securities assumed coverage on Heron Therapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $47.00 target price on the stock. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 23rd. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Heron Therapeutics in a research report on Wednesday, April 15th. Finally, Guggenheim started coverage on Heron Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $24.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $36.10.
HRTX opened at $14.71 on Monday. The business’s fifty day simple moving average is $18.33 and its 200 day simple moving average is $18.49. Heron Therapeutics has a 52 week low of $9.60 and a 52 week high of $26.81. The firm has a market cap of $1.33 billion, a P/E ratio of -6.48 and a beta of 1.55. The company has a quick ratio of 4.17, a current ratio of 4.53 and a debt-to-equity ratio of 0.05.
Several institutional investors have recently added to or reduced their stakes in HRTX. Franklin Resources Inc. raised its holdings in shares of Heron Therapeutics by 19.6% in the 4th quarter. Franklin Resources Inc. now owns 12,361,411 shares of the biotechnology company’s stock worth $290,496,000 after purchasing an additional 2,026,380 shares during the period. Norges Bank purchased a new stake in shares of Heron Therapeutics during the 4th quarter valued at about $23,384,000. Farallon Capital Management LLC purchased a new stake in shares of Heron Therapeutics during the 4th quarter valued at about $20,563,000. Goldman Sachs Group Inc. raised its holdings in shares of Heron Therapeutics by 122.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,537,619 shares of the biotechnology company’s stock valued at $36,134,000 after buying an additional 847,578 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Heron Therapeutics by 27.5% during the 1st quarter. JPMorgan Chase & Co. now owns 2,577,742 shares of the biotechnology company’s stock valued at $30,262,000 after buying an additional 555,540 shares during the period.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Article: Why do analysts give a neutral rating?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.